Africa In Vitro Diagnostics Market by Product & Services, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), Customer Type - Forecast to 2029
The Africa IVD market is expected to grow at a CAGR of 4.8% from 2022 to 2029 to reach $1.78 billion by 2029
Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.
The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major drivers for the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are the major challenges to the market’s growth.
Based on product category, in 2022, the reagents, assays, and kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent use of assays & kits in the detection of various chronic diseases coupled with the high burden of infectious diseases in African countries.
Based on technology, in 2022, the immunoassay segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the advantages of immunoassays, such as simplicity, high accuracy standards, high throughput capability, and inherent specificity.
Based on application, in 2022, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is primarily attributed to the high prevalence of infectious diseases such as COVID-19, dengue, HIV, and Chagas disease in the region and the rising initiatives to boost testing capabilities.
Based on diagnostic approach, in 2022, the laboratory testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests and the higher accuracy offered by laboratory testing.
Based on customer type, in 2022, the hospital laboratories testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high demand for IVD diagnostics and the higher preference for hospitals as the primary center of care.
Based on geography, in 2022, South Africa is expected to account for the largest share of this market. The major share of this region is mainly attributed to the high burden of diseases, the rising geriatric population, the increasing initiatives to promote diagnostic testing, and continuous efforts to develop healthcare infrastructure and promote awareness.
The key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
The Africa IVD market is expected to grow at a CAGR of 4.8% from 2022 to 2029 to reach $1.78 billion by 2029
Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.
The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major drivers for the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are the major challenges to the market’s growth.
Based on product category, in 2022, the reagents, assays, and kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent use of assays & kits in the detection of various chronic diseases coupled with the high burden of infectious diseases in African countries.
Based on technology, in 2022, the immunoassay segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the advantages of immunoassays, such as simplicity, high accuracy standards, high throughput capability, and inherent specificity.
Based on application, in 2022, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is primarily attributed to the high prevalence of infectious diseases such as COVID-19, dengue, HIV, and Chagas disease in the region and the rising initiatives to boost testing capabilities.
Based on diagnostic approach, in 2022, the laboratory testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests and the higher accuracy offered by laboratory testing.
Based on customer type, in 2022, the hospital laboratories testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high demand for IVD diagnostics and the higher preference for hospitals as the primary center of care.
Based on geography, in 2022, South Africa is expected to account for the largest share of this market. The major share of this region is mainly attributed to the high burden of diseases, the rising geriatric population, the increasing initiatives to promote diagnostic testing, and continuous efforts to develop healthcare infrastructure and promote awareness.
The key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
Scope of the Report:
Africa IVD Market, by Product Category
- Reagents, Assays, and Kits
- Instruments
- Software & Services
Africa IVD Market, by Technology
- Immunoassay
- Whole Blood Glucose Monitoring
- Point-of-Care Diagnostics
- Clinical Chemistry
- Molecular Diagnostics
- Hematology
- Coagulation & Hemostasis
- Critical Care
- Urinalysis
- Other IVD Technologies
Africa IVD Market, by Application
- Infectious Diseases
- Diabetes
- Oncology
- Endocrinology
- Cardiology
- Other Applications
Africa IVD Market, by Diagnostic Approach
- Laboratory Testing
- Point-of-Care Testing
- OTC/Self-testing
Africa IVD Market, by Customer Type
- Hospital Labs
- Private Labs
- Home Care/Self Testing
- Government
- Other Customer Types
Note: Other customer types include long-term care facilities, academic & research institutes, ambulatory care centers, and transfusion laboratories
Africa IVD Market, by Country
- South Africa
- Egypt
- Nigeria
- Kenya
- Algeria
- Tanzania
- Morocco
- Tunisia
- Rest of Africa
Table of Contents
1. Introduction1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Dynamics
4.1. Market Overview
4.2. Drivers
4.2.1. Government Initiatives Supporting Africa’s Healthcare Sector
4.2.2. Rising Prevalence of Communicable and Noncommunicable Diseases
4.2.3. Key Market Players’ Increasing Investments in Africa’s IVD Sector
4.3. Restraints
4.3.1. High Prices of IVD Products
4.4. Opportunities
4.4.1. Increasing Awareness About the Importance of Early Diagnosis
4.5. Challenges
4.5.1. Uneven Access to Healthcare
4.5.2. Shortage of Trained Healthcare Personnel
5. Africa IVD Market, by Product Category
5.1. Introduction
5.2. Reagents, Assays, and Kits
5.3. Instruments
5.4. Software & Services
6. Africa IVD Market, by Technology
6.1. Introduction
6.2. Immunoassay
6.3. Whole Blood Glucose Monitoring
6.4. Point-of-Care Diagnostics
6.5. Clinical Chemistry
6.6. Molecular Diagnostics
6.7. Hematology
6.8. Coagulation & Hemostasis
6.9. Critical Care
6.10. Urinalysis
6.11. Other IVD Technologies
7. Africa IVD Market, by Application
7.1. Introduction
7.2. Infectious Diseases
7.3. Oncology
7.4. Diabetes
7.5. Endocrinology
7.6. Cardiology
7.7. Other Applications
8. Africa IVD Market, by Diagnostic Approach
8.1. Introduction
8.2. Laboratory Testing
8.3. Point-of-Care Testing
8.4. OTC/Self-Testing
9. Africa In Vitro Diagnostics Market, by Customer Type
9.1. Introduction
9.2. Hospital Labs
9.3. Private Labs
9.4. Home Care/Self-Testing
9.5. Government
9.6. Other Customer Types
10. Africa IVD Market, by Geography
10.1. Introduction
10.2. South Africa
10.3. Egypt
10.4. Nigeria
10.5. Kenya
10.6. Algeria
10.7. Tanzania
10.8. Morocco
10.9. Tunisia
10.10. Rest of Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2021)
11.4.1. F. Hoffmann-La Roche Ltd (Switzerland)
11.4.2. Abbott Laboratories (U.S.)
11.4.3. Danaher Corporation (U.S.)
12. Company Profiles (Business Overview, Financial Overview, Solutions Portfolio, Strategic Developments)
12.1. Abbott Laboratories
12.2. Becton, Dickinson and Company
12.3. bioMérieux SA
12.4. Danaher Corporation
12.5. F. Hoffmann-La Roche Ltd
12.6. QIAGEN N.V.
12.7. Siemens Healthineers AG (Subsidiary of Siemens AG)
12.8. Thermo Fisher Scientific Inc.
12.9. Bio-Rad Laboratories, Inc.
12.10. Illumina, Inc.
12.11. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
13. Appendix
13.1. Questionnaire
Companies Mentioned
- Abbott Laboratories (U.S.)
- Becton Dickinson and Company (U.S.)
- bioMérieux SA (France)
- Danaher Corporation (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- QIAGEN N.V. (Netherlands)
- Siemens Healthineers AG (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Illumina Inc. (U.S.)
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd (China).